The FDA has expanded approval of the breast cancer drug to include post-surgery therapy for patients with early breast cancer, Pfizer said. The tablets have been approved since 1999 for treating advanced breast cancer after standard chemotherapy, and a study showed women who switched to Aromasin after two to three years of tamoxifen were more likely to avoid a cancer recurrence than those who continued with tamoxifen.

Related Summaries